MONTREAL, Aug. 6, 2024 /CNW/ - Valeo Pharma Inc. (TSX:VPH.TO) (OTC-BB:VPHIF) (FSE:VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that the Company's Chief Development Officer, Mr. Al Moghaddam, has been appointed to succeed retiring CEO Steve Saviuk.
Read more at newswire.caVALEO PHARMA ANNOUNCES LEADERSHIP CHANGES
Newswire.ca - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here